Literature DB >> 16043507

Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap.

Yifei Yan1, Yuri Svitkin, Joseph M Lee, Martin Bisaillon, Jerry Pelletier.   

Abstract

Ribavirin is a guanosine ribonucleoside analog that displays broad-spectrum anti-viral activity and is currently used for the treatment of some viral infections. Ribavirin has recently been proposed to also be a mimic of the 7-methyl guanosine cap found at the 5' end of mRNAs. To obtain supporting functional data for this hypothesis, we assessed the ability of ribavirin triphosphate to interfere with the interaction between eIF4E and 7-methyl guanosine capped mRNA. In chemical cross-linking assays, cap-affinity chromatography, and cap-dependent translation assays, ribavirin was unable to function as a cap analog.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16043507      PMCID: PMC1370807          DOI: 10.1261/rna.2930805

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  42 in total

1.  A noncommercial dual luciferase enzyme assay system for reporter gene analysis.

Authors:  B W Dyer; F A Ferrer; D K Klinedinst; R Rodriguez
Journal:  Anal Biochem       Date:  2000-06-15       Impact factor: 3.365

Review 2.  Mechanisms of action of ribavirin in antiviral therapies.

Authors:  R C Tam; J Y Lau; Z Hong
Journal:  Antivir Chem Chemother       Date:  2001-09

3.  Inhibitors of protein synthesis identified by a high throughput multiplexed translation screen.

Authors:  Olivia Novac; Anne-Sophie Guenier; Jerry Pelletier
Journal:  Nucleic Acids Res       Date:  2004-02-09       Impact factor: 16.971

4.  Inhibition of eukaryotic translation by analogues of messenger RNA 5'-cap: chemical and biological consequences of 5'-phosphate modifications of 7-methylguanosine 5'-monophosphate.

Authors:  E Darzynkiewicz; I Ekiel; P Lassota; S M Tahara
Journal:  Biochemistry       Date:  1987-07-14       Impact factor: 3.162

5.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.

Authors:  S Crotty; D Maag; J J Arnold; W Zhong; J Y Lau; Z Hong; R Andino; C E Cameron
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

6.  RNA virus error catastrophe: direct molecular test by using ribavirin.

Authors:  S Crotty; C E Cameron; R Andino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

Review 7.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

8.  Cell-free synthesis of encephalomyocarditis virus.

Authors:  Yuri V Svitkin; Nahum Sonenberg
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

9.  An efficient system for cap- and poly(A)-dependent translation in vitro.

Authors:  Yuri V Svitkin; Nahum Sonenberg
Journal:  Methods Mol Biol       Date:  2004

10.  Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin.

Authors:  D Maag; C Castro; Z Hong; C E Cameron
Journal:  J Biol Chem       Date:  2001-10-15       Impact factor: 5.157

View more
  23 in total

Review 1.  Further evidence that ribavirin interacts with eIF4E.

Authors:  Alex Kentsis; Laurent Volpon; Ivan Topisirovic; Clifford E Soll; Biljana Culjkovic; Ling Shao; Katherine L B Borden
Journal:  RNA       Date:  2005-10-26       Impact factor: 4.942

Review 2.  Targeting the translation machinery in cancer.

Authors:  Mamatha Bhat; Nathaniel Robichaud; Laura Hulea; Nahum Sonenberg; Jerry Pelletier; Ivan Topisirovic
Journal:  Nat Rev Drug Discov       Date:  2015-03-06       Impact factor: 84.694

3.  The antiviral drug ribavirin does not mimic the 7-methylguanosine moiety of the mRNA cap structure in vitro.

Authors:  Belinda Westman; Lisa Beeren; Ewa Grudzien; Janusz Stepinski; Remigiusz Worch; Joanna Zuberek; Jacek Jemielity; Ryszard Stolarski; Edward Darzynkiewicz; Robert E Rhoads; Thomas Preiss
Journal:  RNA       Date:  2005-08-30       Impact factor: 4.942

Review 4.  The biological and therapeutic relevance of mRNA translation in cancer.

Authors:  Sarah P Blagden; Anne E Willis
Journal:  Nat Rev Clin Oncol       Date:  2011-03-01       Impact factor: 66.675

5.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

Review 6.  Targeting the eIF4F translation initiation complex: a critical nexus for cancer development.

Authors:  Jerry Pelletier; Jeremy Graff; Davide Ruggero; Nahum Sonenberg
Journal:  Cancer Res       Date:  2015-01-15       Impact factor: 12.701

Review 7.  Hippuristanol - A potent steroid inhibitor of eukaryotic initiation factor 4A.

Authors:  Regina Cencic; Jerry Pelletier
Journal:  Translation (Austin)       Date:  2016-01-04

Review 8.  Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.

Authors:  Peter B Bitterman; Vitaly A Polunovsky
Journal:  Mol Cancer Ther       Date:  2012-05       Impact factor: 6.261

Review 9.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

10.  The immunosuppressive agent mizoribine monophosphate is an inhibitor of the human RNA capping enzyme.

Authors:  Frédéric Picard-Jean; Isabelle Bougie; Satoshi Shuto; Martin Bisaillon
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.